Cargando…
Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
BACKGROUND: To investigate the prognostic factors affecting long-term survival in locally advanced cervical cancer (LACC) patients treated with concurrent chemoradiotherapy (CCRT). METHODS: We retrospectively analyzed 192 naive LACC (stage IIB–IVA) patients who underwent intensity-modulated radiothe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386993/ https://www.ncbi.nlm.nih.gov/pubmed/35978412 http://dx.doi.org/10.1186/s13014-022-02115-1 |
_version_ | 1784769931553800192 |
---|---|
author | Liu, Jing Tang, Guyu Zhou, Qin Kuang, Weilu |
author_facet | Liu, Jing Tang, Guyu Zhou, Qin Kuang, Weilu |
author_sort | Liu, Jing |
collection | PubMed |
description | BACKGROUND: To investigate the prognostic factors affecting long-term survival in locally advanced cervical cancer (LACC) patients treated with concurrent chemoradiotherapy (CCRT). METHODS: We retrospectively analyzed 192 naive LACC (stage IIB–IVA) patients who underwent intensity-modulated radiotherapy (IMRT) with concurrent platinum-based chemotherapy in Xiangya Hospital from January 2014 to June 2017. The clinicopathological factors of all patients were collected. To explore the relationship between factors and prognosis, survival rates were estimated by the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to evaluate the effect of various factors on overall survival (OS) and progression-free survival (PFS). The nomogram and calibration curves were generated on the basis of survival analysis. RESULTS: The median follow-up time was 39.5 months. There-year rates of OS and PFS were 89.1% and 82.8%. LACC patients with non-squamous cell carcinoma [NSCC, including adenocarcinoma or adenosquamous carcinoma (AC/ASC)], advanced stage (IIIA-IVA), initially positive lymph node (pelvic or para-aortic lymph node, PLN/PALN), and a lower pretreatment hemoglobin (HGB) level (< 126 g/L) had lower survival rates. In univariate analysis, patients with NSCC, advanced stage, PLN or PALN metastasis had worse OS. Patients with NSCC, advanced stage, PLN or PALN metastasis, and a lower pretreatment HGB level had worse PFS. In multivariate analysis, NSCC and PALN metastasis were independent prognostic parameters of OS. NSCC, PALN metastasis and a lower pretreatment HGB level were independent prognostic parameters of PFS. CONCLUSIONS: NSCC and PALN metastasis were poor prognostic factors of OS and PFS, a lower pretreatment HGB level was an independent prognostic factor of PFS in LACC patients treated with CCRT. |
format | Online Article Text |
id | pubmed-9386993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93869932022-08-19 Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy Liu, Jing Tang, Guyu Zhou, Qin Kuang, Weilu Radiat Oncol Research BACKGROUND: To investigate the prognostic factors affecting long-term survival in locally advanced cervical cancer (LACC) patients treated with concurrent chemoradiotherapy (CCRT). METHODS: We retrospectively analyzed 192 naive LACC (stage IIB–IVA) patients who underwent intensity-modulated radiotherapy (IMRT) with concurrent platinum-based chemotherapy in Xiangya Hospital from January 2014 to June 2017. The clinicopathological factors of all patients were collected. To explore the relationship between factors and prognosis, survival rates were estimated by the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to evaluate the effect of various factors on overall survival (OS) and progression-free survival (PFS). The nomogram and calibration curves were generated on the basis of survival analysis. RESULTS: The median follow-up time was 39.5 months. There-year rates of OS and PFS were 89.1% and 82.8%. LACC patients with non-squamous cell carcinoma [NSCC, including adenocarcinoma or adenosquamous carcinoma (AC/ASC)], advanced stage (IIIA-IVA), initially positive lymph node (pelvic or para-aortic lymph node, PLN/PALN), and a lower pretreatment hemoglobin (HGB) level (< 126 g/L) had lower survival rates. In univariate analysis, patients with NSCC, advanced stage, PLN or PALN metastasis had worse OS. Patients with NSCC, advanced stage, PLN or PALN metastasis, and a lower pretreatment HGB level had worse PFS. In multivariate analysis, NSCC and PALN metastasis were independent prognostic parameters of OS. NSCC, PALN metastasis and a lower pretreatment HGB level were independent prognostic parameters of PFS. CONCLUSIONS: NSCC and PALN metastasis were poor prognostic factors of OS and PFS, a lower pretreatment HGB level was an independent prognostic factor of PFS in LACC patients treated with CCRT. BioMed Central 2022-08-17 /pmc/articles/PMC9386993/ /pubmed/35978412 http://dx.doi.org/10.1186/s13014-022-02115-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liu, Jing Tang, Guyu Zhou, Qin Kuang, Weilu Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
title | Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
title_full | Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
title_fullStr | Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
title_full_unstemmed | Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
title_short | Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
title_sort | outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386993/ https://www.ncbi.nlm.nih.gov/pubmed/35978412 http://dx.doi.org/10.1186/s13014-022-02115-1 |
work_keys_str_mv | AT liujing outcomesandprognosticfactorsinpatientswithlocallyadvancedcervicalcancertreatedwithconcurrentchemoradiotherapy AT tangguyu outcomesandprognosticfactorsinpatientswithlocallyadvancedcervicalcancertreatedwithconcurrentchemoradiotherapy AT zhouqin outcomesandprognosticfactorsinpatientswithlocallyadvancedcervicalcancertreatedwithconcurrentchemoradiotherapy AT kuangweilu outcomesandprognosticfactorsinpatientswithlocallyadvancedcervicalcancertreatedwithconcurrentchemoradiotherapy |